Anti-PLET1/ C11orf34 monoclonal antibody

Anti-PLET1/ C11orf34 antibody for FACS & in-vivo assay

Target products collectionGo to PLET1/PLET1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1382-Ab-1/ GM-Tg-hg-MP1382-Ab-2Anti-Human PLET1 monoclonal antibodyHuman
GM-Tg-rg-MP1382-Ab-1/ GM-Tg-rg-MP1382-Ab-2Anti-Rat PLET1 monoclonal antibodyRat
GM-Tg-mg-MP1382-Ab-1/ GM-Tg-mg-MP1382-Ab-2Anti-Mouse PLET1 monoclonal antibodyMouse
GM-Tg-cynog-MP1382-Ab-1/ GM-Tg-cynog-MP1382-Ab-2Anti-Cynomolgus/ Rhesus macaque PLET1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1382-Ab-1/ GM-Tg-felg-MP1382-Ab-2Anti-Feline PLET1 monoclonal antibodyFeline
GM-Tg-cang-MP1382-Ab-1/ GM-Tg-cang-MP1382-Ab-2Anti-Canine PLET1 monoclonal antibodyCanine
GM-Tg-bovg-MP1382-Ab-1/ GM-Tg-bovg-MP1382-Ab-2Anti-Bovine PLET1 monoclonal antibodyBovine
GM-Tg-equg-MP1382-Ab-1/ GM-Tg-equg-MP1382-Ab-2Anti-Equine PLET1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1382-Ab-1/ GM-Tg-hg-MP1382-Ab-2; GM-Tg-rg-MP1382-Ab-1/ GM-Tg-rg-MP1382-Ab-2;
GM-Tg-mg-MP1382-Ab-1/ GM-Tg-mg-MP1382-Ab-2; GM-Tg-cynog-MP1382-Ab-1/ GM-Tg-cynog-MP1382-Ab-2;
GM-Tg-felg-MP1382-Ab-1/ GM-Tg-felg-MP1382-Ab-2; GM-Tg-cang-MP1382-Ab-1/ GM-Tg-cang-MP1382-Ab-2;
GM-Tg-bovg-MP1382-Ab-1/ GM-Tg-bovg-MP1382-Ab-2; GM-Tg-equg-MP1382-Ab-1/ GM-Tg-equg-MP1382-Ab-2
Products NameAnti-PLET1 monoclonal antibody
Formatmab
Target NamePLET1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PLET1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PLET1/ C11orf34 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1382
    Target NamePLET1
    Gene ID349633,76509,363060,114672396,102156295,102899342,102148536
    Gene Symbol and Synonyms0610037B23Rik,1600029D21Rik,C11orf34,C5H11orf34,C7H11orf34,PLET1
    Uniprot AccessionQ6UQ28,Q5HZW7
    Uniprot Entry NamePLET1_HUMAN,PLET1_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188771
    Target ClassificationN/A

    The target: PLET1, gene name: PLET1, also named as C11orf34. Predicted to be involved in negative regulation of cell-matrix adhesion; positive regulation of cell migration; and wound healing, spreading of epidermal cells. Predicted to be located in extracellular region and plasma membrane. Predicted to be active in apical plasma membrane and external side of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.